Abstract:Background: Farnesoid X receptor (FXR), a bile acid-sensing nuclear receptor, is widely implicated in the tumorigenesis of various human cancers. The FXR agonist obeticholic acid (OCA) has preliminarily displayed tumor suppressor potential. However, the anticancer effects of this agent on colorectal cancer (CRC) remain unclear. Methods: A series of functional assays in vivo and in vitro was utilized to observe the effect of OCA treatment on colon cancer cells. Real-time PCR, western blot, immunofluorescence (IF) and immunocytochemistry (ICC) assays were conducted to measure the expression of cell cycle-, apoptosis- and EMT-related genes and JAK2/STAT3 signaling. Dual luciferase reporter and quantitative chromatin immunoprecipitation (qChIP) assays were performed to confirm whether FXR bound to a specific region of the SOCS3 promoter. Co-immunoprecipitation (co-IP) assay was used to identify the interaction between β-catenin and FXR. Findings: Treatment of colon cancer cells with OCA inhibited cell proliferation and invasion in vitro, retarded tumor formation in vivo and prevented the G0/G1 to S phase transition. Mechanistic studies indicated that OCA treatment suppressed the activity of the JAK2/STAT3 pathway by FXR-mediated transcriptional activation of SOCS3 expression. Furthermore, we identified an interaction between β-catenin and FXR in colon cancer cells. OCA treatment induced the dissociation of the FXR/β-catenin complex. Loss of β-catenin dramatically expedited FXR nuclear translocation and increased its occupancy of the SOCS3 promoter after OCA exposure. Interpretation: Our study identified a novel molecular mechanism whereby FXR activation led to anticancer effects in CRC. Funding Statement: This work was funded by a grant from the National Natural Science Foundation of China (Grant Serial Numbers: 81972720, 81101874, 81172362), the Coordinative and Innovative Plan Projects of the Science and Technology Program in Shaanxi Province (Grant Serial Numbers: 2013KTCQ03-08), the Science and Technology Project of Shaanxi Province (Grant serial number: 2016SF-015, 2019SF-065, 2016SF-015), the Fundamental Research Funds for the Central Universities (Grant serial number: xjj2018123). Declaration of Interests: The authors declare that they have no conflicts of interest. Ethics Approval Statement: The use of all animals in this study was approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Xi’an Jiaotong University.

FAXC interacts with ANXA2 and SRC in mitochondria and promotes tumorigenesis in cholangiocarcinoma

NUF2 Drives Cholangiocarcinoma Progression and Migration Via Inhibiting Autophagic Degradation of TFR1

Fyn Knockdown Inhibits Migration and Invasion in Cholangiocarcinoma Through the Activated AMPK/mTOR Signaling Pathway

Annexin10 Promotes Extrahepatic Cholangiocarcinoma Metastasis by Facilitating EMT Via PLA2G4A/PGE2/STAT3 Pathway

Targeting The Fgfr Signaling Pathway In Cholangiocarcinoma: Promise Or Delusion?

Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway

KIF14 promotes proliferation, lymphatic metastasis and chemoresistance through G3BP1/YBX1 mediated NF-κB pathway in cholangiocarcinoma

ZNF460-mediated upregulation of APCDD1L-DT promotes cholangiocarcinoma development by inhibiting the ubiquitin-mediated degradation of DVL2

Farnesoid X Receptor Activation Inhibits the Growth and Metastasis of Colorectal Cancer by Suppressing JAK2/STAT3 Signaling Via Induction of the Dissociation of the FXR/β-Catenin Complex

Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2

FXR Acts As a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.

Circ_0020256 Induces Fibroblast Activation to Drive Cholangiocarcinoma Development Via Recruitment of EIF4A3 Protein to Stabilize KLF4 Mrna

Identification of Chondroitin Polymerizing Factor (CHPF) As Tumor Promotor in Cholangiocarcinoma Through Regulating Cell Proliferation, Cell Apoptosis and Cell Migration

AKT2 S128 /CCTα S315/319/323 -positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs)

Cancer-associated Adipocytes Release FUCA2 to Promote Aggressiveness in TNBC

Oncogenic Role of the NFATC2/NEDD4/FBP1 Axis in Cholangiocarcinoma

Cancer-Associated Adipocytes Release FUCA2 to Promote Aggressive Phenotype in Triple-Negative Breast Cancer

FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth

Cancer-associated Fibroblast-Derived Stanniocalcin 1 Promotes Cholangiocarcinoma Progression and Lymph Node Metastasis

FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis

ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun